SCYNEXIS to Participate in September Investor Conferences
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from…
New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company…
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions…
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions…
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling…
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling…
Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal…
Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal…
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into…
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into…